Clinical Trials

Other hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Phase 1/2 Completed

27 enrolled 12 charts

Hematologic Neoplasms

NCT01134575 2024-07-16

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

90 enrolled 10 charts

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Phase 2 Terminated

4 enrolled 11 charts

Burkitt Lymphoma

NCT03677596 2023-11-22

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Phase 4 Completed

102 enrolled 27 charts

MyeloidOther hematologic neoplasm

Leukemia, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02311998 2023-07-17

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Phase 1/2 Completed

22 enrolled 14 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01925131 2023-05-03

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

50 enrolled 14 charts

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03094611 2021-04-12

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Phase 2 Terminated

4 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01055496 2019-08-02

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

103 enrolled 20 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00724971 2019-03-15

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

10 enrolled 13 charts

326 enrolled 33 charts 1 FDA

Lymphoma, B-Cell

NCT01564784 2019-01-09

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Phase 3 Completed

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01232556 2019-01-08

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Phase 3 Terminated

338 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00073749 2018-12-17

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

79 enrolled 24 charts

Lymphoma, Lymphoma, B-Cell

NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Phase 1/2 Completed

119 enrolled 60 charts

Lymphoma, Lymphoma, B-Cell

NCT00562965 2018-01-09

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Phase 3 Terminated

29 enrolled 14 charts

Lymphoma, Follicular

NCT00867087 2017-12-05

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

64 enrolled 15 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00868608 2017-10-31

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

81 enrolled 24 charts

Lymphoma

NCT01363297 2017-04-13

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

72 enrolled 27 charts